INX-315 Dosage Regimens for Reduced Plasma Concentration Spikes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CDK2 inhibitors like BLU-222 and PF-07104091 exhibit plasma concentration spikes leading to side effects, necessitating improved treatment regimes for CDK4/6-resistant tumors with reduced off-target toxicities.
Innovation Solution
INX-315 is formulated as an amorphous spray-dried dispersion with a precipitation preventer, resulting in reduced plasma concentration spikes and sustained release, enhancing bioavailability and efficacy in treating both Rb-dependent and Rb-independent cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CDK2 inhibitors like BLU-222 and PF-07104091 are administered to treat cancer, then anti-cancer efficacy is improved, but plasma concentration spikes occur leading to off-target toxicities and side effects
Solution Approach 1:
The patent employs periodic dosing regimens (e.g., once-weekly, once-every-two-weeks) to maintain sustained drug exposure while allowing plasma concentrations to stabilize between doses, avoiding the harmful spikes associated with more frequent dosing. This periodic administration strategy enables continuous anti-cancer efficacy while minimizing off-target toxicities.
Solution Approach 2:
The patent utilizes amorphous spray-dried dispersion formulation to fundamentally change the physical state and dissolution characteristics of INX-315. This parameter change in drug formulation enables controlled release and sustained exposure profiles, transforming the pharmacokinetic behavior from spike-prone to stable, predictable exposure that maintains efficacy while reducing toxicities.
2Speed
If conventional CDK2 inhibitors are administered, then initial plasma concentration spikes occur, but this leads to increased Cmax to Cmin ratio and adverse events
Solution Approach 1:
The amorphous spray-dried dispersion formulation changes the dissolution rate parameter of INX-315, enabling gradual release into plasma rather than rapid absorption. This parameter change in drug delivery transforms the concentration-time profile from spike-dominated to sustained, maintaining therapeutic levels while avoiding adverse events associated with high Cmax to Cmin ratios.
Solution Approach 2:
The amorphous dispersion system acts as an intermediary between drug administration and plasma absorption, controlling the rate and pattern of drug release. This intermediary formulation approach mediates the transition from rapid spike-prone absorption to controlled sustained release, eliminating adverse events while preserving anti-cancer efficacy.
3Stability of the object's composition
If INX-315 is formulated as amorphous spray-dried dispersion with precipitation preventer, then sustained release and reduced plasma concentration spikes are achieved, but formulation complexity increases
Solution Approach 1:
The patent creates a composite amorphous spray-dried dispersion system combining INX-315 with precipitation preventers and other excipients in specific ratios. This composite material approach achieves sustained release and stable drug exposure profiles while managing the complexity through established pharmaceutical formulation techniques and standardized manufacturing processes.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
INX-315 achieves a low Cmax to Cmin ratio, extended half-life, and higher binding to red blood cells, effectively treating various cancers with minimal side effects, including CDK4/6-resistant tumors and Rb-independent cancers.
Implementation Method 1
it is proposed that INX-315 binds to human blood cells in vivo to a much greater degree than seen in other tested mammals or as predicted prior to human administration. This increases the amount of drug available in human blood and creates a depot effect for a type of extended availability of the drug as it is released over time from the red blood cells into the plasma
Implementation Method 2
INX-315 is formulated as an amorphous spray-dried dispersion with a precipitation preventer, resulting in reduced plasma concentration spikes and sustained release
Implementation Method 3
INX-315 is formulated as an amorphous spray-dried dispersion with a precipitation preventer
Data Source
AI summary
Dosages and regimens based on the discovery of unexpectedly high and sustained exposure of INX-315 in humans in need thereof which results in increased efficacy per dose and minimizes adverse events during treatment, including by minimizing the ratio of Cmax to Cmin, resulting in a decrease in an initial drug spike after administration.